Role of immunotherapy in cancer management
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20250344Keywords:
Immunotherapy, Checkpoint inhibitors, CAR-T cell therapy, Oncolytic virus therapyAbstract
Cancer remains one of the leading causes of mortality worldwide accounting for nearly 20 million new cases and 10 million deaths, prompting continuous research for more effective treatments. In recent years’ immunotherapy has transformed the landscape of cancer treatment, with significant breakthroughs promising more targeted and durable outcomes. Unlike standard treatments, such as surgery, chemotherapy, and radiation, which directly target cancer cells, immunotherapy aims to boost or replace the immune system's natural ability to fight cancer. Since it is a new mode of therapy most of the practicing doctors are unaware of the details about it. In this context, we conducted a narrative review based on available literature. This article explores the historical background and evolution of immunotherapy, the mechanisms of various immunotherapeutic plans, recent advancements, future directions, and challenges in this field. Our paper focused on, checkpoint inhibitors, chimeric antigen receptor T (CAR-T) cell therapy, oncolytic virus therapy, and cancer vaccines. As the field continues to evolve, collaboration among researchers, clinicians, and patients is essential to drive these advancements and improve outcomes in cancer care.
Metrics
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. DOI: https://doi.org/10.3322/caac.21660
Chanana R, Noronha V, Joshi A, Patil V, Prabhash K. Evolving role of immunotherapy in head-and-neck cancers: A systemic review. J Head Neck Physicians Surg. 2018;6(2). DOI: https://doi.org/10.4103/jhnps.jhnps_10_18
Neal ME, Haring CT, Mann JE, Brenner JC, Spector ME, Swiecicki P. Immunotherapeutic approaches in head and neck cancer. Cancer Metastasis Treat. 2019;5:76. DOI: https://doi.org/10.20517/2394-4722.2019.32
Met Ö, Jensen KM, Chamberlain CA, Donia M, Svane IM. Principles of adoptive T cell therapy in cancer. SeminImmunopathol. 2019;41(1):49-58.
Yu Y, Cui J. Present and future of cancer immunotherapy: A tumor microenvironmental perspective (Review). OncolLett. 2018;16(4):4105-13. DOI: https://doi.org/10.3892/ol.2018.9219
Mohan SP, Bhaskaran MK, George AL, Thirutheri A, Somasundaran M, Pavithran A. Immunotherapy in oral cancer. J Pharm Bioallied Sci. 2019;11(Suppl 1):S107-11. DOI: https://doi.org/10.4103/JPBS.JPBS_31_19
Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell MolImmunol. 2020;17(8):807-21.
Decker WK, Safdar A. Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley’s legacy revisited. Cytokine Growth Factor Rev. 2009;20(4):271-81. DOI: https://doi.org/10.1016/j.cytogfr.2009.07.004
Cohen EE, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019;7(1):184. DOI: https://doi.org/10.1186/s40425-019-0662-5
Menon S, Shin S, Dy G. Advances in cancer immunotherapy in solid tumors. Cancers (Basel). 2016;8(12):106.
Grillo-López AJ, White CA, Dallaire BK, Varns C, Shen CD, Wei A, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol. 2000;1(1):1-9. DOI: https://doi.org/10.2174/1389201003379059
Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel). 2011;3(4):3856-93. DOI: https://doi.org/10.3390/cancers3043856
Waldmann TA. Cytokines in cancer immunotherapy. Cold Spring HarbPerspect Biol. 2018;10(12):a028472. DOI: https://doi.org/10.1101/cshperspect.a028472
Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology.2016;5(6):e1163462. DOI: https://doi.org/10.1080/2162402X.2016.1163462
Smyth MJ, O'Donnell JS, Teng MWL. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev ClinOncol. 2019;16(3):151-67 DOI: https://doi.org/10.1038/s41571-018-0142-8
Menon S, Shin S, Dy G. Advances in cancer immunotherapy in solid tumors. Cancers (Basel). 2016;8:106. DOI: https://doi.org/10.3390/cancers8120106
Mei Z, Huang J, Qiao B, Lam AK. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. Int J Oral Sci. 2020;12:1. DOI: https://doi.org/10.1038/s41368-020-0084-8
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386:24-34. DOI: https://doi.org/10.1056/NEJMoa2109970
Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation. J Biol Chem. 2012;287:9429-40. DOI: https://doi.org/10.1074/jbc.M111.304329
De Vicente JC, Rodríguez-Santamarta T, Rodrigo JP, Blanco-Lorenzo V, Allonca E, García-Pedrero JM. PD-L1 expression in tumor cells is an independent unfavorable prognostic factor in oral squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2019;28:546-54. DOI: https://doi.org/10.1158/1055-9965.EPI-18-0779
Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847-56. DOI: https://doi.org/10.1158/1535-7163.MCT-14-0983
Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116:1757-66. DOI: https://doi.org/10.1002/cncr.24899
Met Ö, Jensen KM, Chamberlain CA, Donia M, Svane IM. Principles of adoptive T cell therapy in cancer. SeminImmunopathol. 2019;41:49-58. DOI: https://doi.org/10.1007/s00281-018-0703-z
Rohaan MW, Wilgenhof S, Haanen JB. Adoptive cellular therapies: The current landscape. Virchows Arch. 2019;474:449-61. DOI: https://doi.org/10.1007/s00428-018-2484-0
Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell MolImmunol. 2020;17:807-21. DOI: https://doi.org/10.1038/s41423-020-0488-6
Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515-48. DOI: https://doi.org/10.1146/annurev.immunol.23.021704.115611
Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182:459-65. DOI: https://doi.org/10.1084/jem.182.2.459
Sadelain M. CD19 CAR T cells. Cell. 2017;171:1471. DOI: https://doi.org/10.1016/j.cell.2017.12.002
De Marco RC, Monzo HJ, Ojala PM. CAR T cell therapy: A versatile living drug. Int J Mol Sci. 2023;24(7):6300. DOI: https://doi.org/10.3390/ijms24076300
Narula G, Keerthivasagam S, Jain H, Dhamne C, Tembhare P, Subramanian PG, et al. Evaluating the safety of HCAR19 (now ActalycabtageneAutoleucel - Actaly-Cel™), a novel humanized CD19-directed chimeric antigen receptor T-cells in pediatric, adolescents, and young adults with relapsed/refractory B-acute lymphoblastic leukemia (ESHA) - Report of phase-1B. Blood. 2023;142(Suppl 1):6878. DOI: https://doi.org/10.1182/blood-2023-180867
DeMaria PJ, Bilusic M. Cancer vaccines. HematolOncolClin North Am. 2019;33:199-214. DOI: https://doi.org/10.1016/j.hoc.2018.12.001
Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY. Therapeutic cancer vaccines. Adv Cancer Res. 2013;119:421-75. DOI: https://doi.org/10.1016/B978-0-12-407190-2.00007-1
Lin MJ, Svensson-Arvelund J, Lubitz GS, Clark R, Boss J, Engleman EG, et al. Cancer vaccines: The next immunotherapy frontier. Nat Cancer. 2022;3:911-26. DOI: https://doi.org/10.1038/s43018-022-00418-6
Kaczmarek M, Poznańska J, Fechner F, Michalska N, Paszkowska S, Napierała A, et al. Cancer vaccine therapeutics: Limitations and effectiveness - A literature review. Cells. 2023;12(17):2159. DOI: https://doi.org/10.3390/cells12172159
Yura Y, Hamada M. Development of oncolyticvirotherapy for the treatment of oral cancer – At the waiting stage for clinical use. Oral Sci Int. 2017;14:1-12. DOI: https://doi.org/10.1016/S1348-8643(16)30016-7
Sambi M, Bagheri L, Szewczuk MR. Current challenges in cancer immunotherapy: Multimodal approaches to improve efficacy and patient response rates. J Oncol. 2019;2019:4508794. DOI: https://doi.org/10.1155/2019/4508794
Willsmore ZN, Coumbe B, Crescioli S, Reci S, Gupta A, Harris RJ, et al. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of melanoma and immune mechanisms of action. Eur J Immunol (2021) 51:544–56. DOI: https://doi.org/10.1002/eji.202048747
Downloads
Published
How to Cite
Issue
Section
